1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hemophilia Partnering 2010-2015

Hemophilia Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

Summary
The Hemophilia Partnering 2010-2015 report provides understanding and access to the hemophilia partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in hemophilia partnering deals
Top hemophilia deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Description

The Hemophilia Partnering 2010-2015 report provides understanding and access to the hemophilia partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in hemophilia partnering deals
Top hemophilia deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Hemophilia Partnering 2010-2015 provides understanding and access to the hemophilia partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of hemophilia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors hemophilia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual hemophilia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of hemophilia partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of hemophilia technologies and products.

Report scope

Hemophilia Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to hemophilia trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in hemophilia dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 35 hemophilia deals
The leading hemophilia deals by value since 2010

In Hemophilia Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Hemophilia Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of hemophilia deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 40 actual hemophilia deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

hemophilia, hematology, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Hemophilia Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hemophilia partnering

2.1. Introduction
2.2. Hemophilia partnering over the years
2.3. Hemophilia partnering by deal type
2.4. Hemophilia partnering industry sector
2.5. Hemophilia partnering by stage of development
2.6. Hemophilia partnering by technology type

Chapter 3 - Average deal terms for hemophilia

3.1 Introduction
3.2 Average deal terms for hemophilia
3.3 Hemophilia headline values with median calculation
3.4 Hemophilia upfront values with median calculation
3.5 Hemophilia milestone values with median calculation
3.6 Hemophilia royalty rates with median calculation

Chapter 4 - Active hemophilia dealmakers

4.1. Introduction
4.2 Most active hemophilia dealmakers
4.3. Top hemophilia deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Hemophilia dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Hemophilia partnering since 2010
Figure 2: Hemophilia dealmaking activity- 2010 to 2015
Figure 3: Hemophilia partnering by deal type since 2010
Figure 4: Hemophilia partnering by industry sector since 2010
Figure 5: Hemophilia partnering by stage of development since 2010
Figure 6: Hemophilia partnering by technology type since 2010
Figure 7: Hemophilia deals with a headline value
Figure 8: Hemophilia deals with upfront payment values
Figure 9: Hemophilia deals with milestone payments
Figure 10: Hemophilia deals with royalty rates, %
Figure 11: Top hemophilia deals by value since 2010
Figure 12: Big pharma - top 50 - hemophilia deals 2010 to 2015
Figure 13: Big pharma hemophilia deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - hemophilia deals 2010 to 2015
Figure 15: Big biotech hemophilia deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.